Method for preparing psoriasis-like 3-dimensional skin tissue model and method for screening therapeutic agents for psoriasis using the same

By treating a three-dimensional skin tissue model with a cytokine complex of IL-17, IL-22, and TNF-α, optionally with feeder cells, psoriasis-like conditions are replicated, enabling effective screening of psoriasis treatments through modulated factor expression and physiological changes.

KR103044320B1Active Publication Date: 2026-11-06BIO SOLUTION CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
KR1020230016328
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2023-02-07
Publication Date
2026-11-06
Estimated Expiration
2043-02-07

AI Technical Summary

Technical Problem

Existing methods fail to accurately replicate psoriasis-like conditions in three-dimensional skin tissue models, limiting the effectiveness of screening psoriasis treatments.

Method used

A method involving treatment of a three-dimensional skin tissue model with a cytokine complex composed of IL-17, IL-22, and TNF-α, optionally with co-culture of feeder cells, to induce psoriasis-like characteristics such as reduced expression of skin barrier and epidermal cell differentiation factors and increased expression of psoriasis disease markers and pro-inflammatory cytokines.

Benefits of technology

The method effectively mimics psoriasis-like conditions, allowing for accurate evaluation and screening of psoriasis treatments by modulating the expression of relevant factors and physiological changes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112023014363714-PAT00002_ABST
    Figure 112023014363714-PAT00002_ABST
Patent Text Reader

Abstract

The present invention relates to a method for manufacturing a psoriasis-like three-dimensional skin tissue model and a method for screening psoriasis therapeutic agents using the same. Specifically, a three-dimensional skin tissue model exhibiting psoriasis-like findings was manufactured by treating the model with a cytokine mix containing IL-7, IL-22, and TNF-α. Furthermore, it was confirmed that candidate substances for psoriasis therapeutic agents can be selected using the model. In addition, it was confirmed that psoriasis findings were more accurately realized in a three-dimensional skin tissue model co-cultured with feeder cells in addition to the cytokine mix treatment. Therefore, the psoriasis-like three-dimensional skin tissue model manufactured according to the method of the present invention can be usefully utilized as a new alternative animal testing method for evaluating the efficacy and studying the mechanism of action of psoriasis therapeutic agents.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a method for manufacturing a psoriasis-like three-dimensional skin tissue model and a method for screening psoriasis treatments using the same. More specifically, the invention relates to a method for manufacturing a psoriasis-like three-dimensional skin tissue model through treatment with a cytokine mix and a method for screening psoriasis treatments using the psoriasis-like three-dimensional skin tissue model manufactured therefrom. Additionally, the invention relates to a method for manufacturing a psoriasis-like three-dimensional skin tissue model through treatment with a cytokine mix and additional co-culture with feeder cells, and a method for screening psoriasis treatments using the psoriasis-like three-dimensional skin tissue model manufactured therefrom. Background Technology

[0003] Psoriasis is a chronic inflammatory skin disease characterized by repeated exacerbations and remissions. Although the exact cause of the disease has not been identified, it is generally reported to be caused by immunological abnormalities. Psoriasis has a global prevalence of approximately 3%, and it is estimated that there are around 1.5 million patients in Korea, with the number of patients on the rise.

[0004] Psoriasis is characterized by the excessive proliferation of epidermal cells due to damage to the skin barrier function, resulting in the accumulation of layers of keratin; blood vessels in the affected area also expand and proliferate, accompanied by erythema (redness). Additionally, as the stratum corneum thickens, dryness in the affected area intensifies, and pruritus (itching) occurs.

[0005] Psoriasis manifests due to epidermal hyperplasia (as evidenced by the Ki67 marker), characterized by inhibited differentiation of keratinocytes and incomplete keratinization (hyperkeratosis) in which cell nuclei remain in the stratum corneum. Recently, interactions between environmental and genetic factors have been reported as the underlying causes of the disease. For instance, triggering factors such as mechanical trauma or bacterial infection initiate a series of reactions including the formation of the DNA-LL37 complex, the activation of plasmacytoid dendritic cells, and the secretion of pro-inflammatory cytokines. Stimulated bone marrow dendritic cells migrate to lymph nodes and differentiate naive T cells into effector cells, such as T helper 1 or 17 cells (Th1 or Th17) or T cytotoxic 1 or 17 cells (Tc1 or Tc17). Immune cells (primarily neutrophils) expressing CXCL1, CXCL2, and CXCL8 receptors migrate to the skin along a chemokine gradient. The major processes during disease persistence are the presentation of putative autoantigens to T lymphocytes and the release of IL-23 by skin dendritic cells, the production of pro-inflammatory mediators such as IL-17A, IL-17F, and IL-22 by Th17 and Tc17 lymphocytes, and the production of IFN-γ and TNF-α by Th1 and Tc1 cells. These mediators act on keratinocytes to induce activation and proliferation, as well as the production of antimicrobial peptides (e.g., LL-37 cathelicidin and β-defensin), chemokines (e.g., CXCL9), and S100 proteins (e.g., S100A7). In addition, simultaneous action of keratinocytes, fibroblasts, immune cells, and endothelial cells involved in tissue reconstruction due to the progression of chronic inflammation occurs (mediated by the PI3K / mTOR pathway).Therefore, the affected skin exhibits abnormal maturation, and mutations or reductions in the expression of some genes of early and terminal differentiation markers (FLG, KRT1, KRT5, KRT10, KRT14, and LOR) are observed (Bochenska, K., Moskot, M., Gabig-Ciminska, M. Cells 2021, 10, 2985).

[0007] Meanwhile, the 3D skin model is a Reconstructed Human Epidermis (RhE) model that reconstructs the human epidermis three-dimensionally by inducing the differentiation of keratinocytes, the major cells constituting the human epidermis, in an air-liquid interface cell culture. This enables numerous studies, including the evaluation of skin irritation, phototoxicity, and corrosiveness. EPISKIN TM , EpiDerm TM , SkinEthic TM , KeraSkin TM Artificial skin models such as the back have been listed in the OECD guidelines, having been certified for their usefulness as an irritation test method to replace animal testing through various validation studies.

[0009] Against this backdrop, the inventors have made efforts to develop an animal substitute psoriasis model that can reflect the human biological environment as much as possible using normal skin tissue cells that are relatively easy to obtain. As a result, they confirmed that psoriasis findings appeared in a 3D skin tissue model treated with a cytokine complex containing IL-17, IL-22, and TNF-α, and confirmed that the characteristics of psoriasis were more accurately realized in a 3D skin tissue model co-cultured with feeder cells in addition to the treatment with the cytokine complex. Accordingly, by revealing that the above model can be used as a psoriasis-like 3D skin tissue model, they have reached the present application. The problem to be solved

[0011] The objective of the present invention is to provide a method for manufacturing a psoriasis-like three-dimensional skin tissue model and a method for screening psoriasis therapeutic agents using the psoriasis-like three-dimensional skin tissue model manufactured therefrom. means of solving the problem

[0013] To achieve the objective of the present invention, the present invention provides a method for manufacturing a psoriasis-like three-dimensional skin tissue model comprising the following steps:

[0014] (a) treating a three-dimensional skin tissue model with a cytokine complex composed of IL-17, IL-22, and TNF-α; and

[0015] (b) A step of confirming the expression of one or more of skin barrier and epidermal cell differentiation factors, psoriasis disease markers, and proinflammatory cytokines in the above-processed three-dimensional skin tissue model.

[0016] In addition, the present invention provides a method for manufacturing a psoriasis-like three-dimensional skin tissue model, further comprising co-culturing the three-dimensional skin tissue model of step (a) with feeder cells.

[0017] In addition, the present invention provides a psoriasis-like three-dimensional skin tissue model manufactured by the above method.

[0018] In addition, the present invention provides a screening method for psoriasis therapeutic agents using a psoriasis-like three-dimensional skin tissue model comprising the following steps:

[0019] (a) a step of treating a psoriasis therapeutic candidate substance to a psoriasis-like three-dimensional skin tissue model prepared by the above method; and

[0020] (b) A step of confirming the expression of one or more of skin barrier and epidermal cell differentiation factors, psoriasis disease markers and pro-inflammatory cytokines in a skin tissue model treated with the above psoriasis treatment candidate substance. Effects of the invention

[0022] In this invention, when a cytokine complex containing IL-17, IL-22, and TNF-α was treated to a three-dimensional skin tissue model, a decrease in the expression of filaggrin, involucrin, loricrin, and cytokeratin-10—which are skin barrier and epidermal cell differentiation factors important findings in psoriatic skin lesions—was observed. Additionally, an increase in the expression of psoriasis disease markers S100A7 (S100 calcium binding protein A7), PI3 (peptidase inhibitor 3), DEFB4 (defensin beta 4B), and Ki-67, as well as the expression of proinflammatory cytokines CXCL10 and IL-8, was observed. Histopathologically, the model mimics characteristics such as parakeratosis, psoriatic hyperplasia, and a reduced granular layer, and physically, the keratin It was confirmed that the thickness and interepithelial electrical resistance (TEER) increased.

[0023] In addition, when the above 3D skin tissue model was treated with dexamethasone, a candidate substance for psoriasis treatment, it was confirmed that the expression of the skin barrier and epidermal cell differentiation factors increased, and the expression of psoriasis disease markers and pro-inflammatory cytokines decreased.

[0024] In addition, it was confirmed that psoriasis findings were more accurately realized in a 3D skin tissue model co-cultured with feeder cells along with the treatment of the above cytokine complex.

[0025] Accordingly, the three-dimensional skin tissue model prepared through cytokine complex treatment according to the method of the present invention, and the three-dimensional skin tissue model prepared through cytokine complex treatment and co-culture of culture-assisted cells, can be usefully utilized as a new animal alternative testing method for evaluating the efficacy and studying the mechanism of psoriasis treatments, as a psoriasis-like three-dimensional skin tissue model. Brief explanation of the drawing

[0027] FIG. 1a is a figure confirming the gene expression of skin barrier and epidermal cell differentiation factors, filaggrin (FLG), involucrin (IVL), loricrin (LOR), and cytokeratin-10 (KRT10), in a psoriasis-like three-dimensional skin tissue model prepared by treatment with a cytokine complex according to one embodiment of the present invention. FIG. 1b is a figure showing the gene expression of psoriasis disease markers S100A7 (S100 calcium binding protein A7), PI3 (Peptidase inhibitor 3), and DEFB4 (Defensin beta 4B) in a psoriasis-like 3D skin tissue model prepared by treatment with a cytokine complex according to one embodiment of the present invention. FIG. 1c is a figure confirming the gene expression of proinflammatory cytokines CXCL10 and IL-8 in a psoriasis-like three-dimensional skin tissue model prepared through treatment with a cytokine complex according to one embodiment of the present invention. FIG. 2a is a figure showing the histopathological characteristics of a psoriasis-like three-dimensional skin tissue model prepared through cytokine complex treatment according to one embodiment of the present invention. FIG. 2b is a figure showing the interepithelial electrical resistance (TEER) in a psoriasis-like three-dimensional skin tissue model prepared through treatment with a cytokine complex according to one embodiment of the present invention. FIG. 3a is a figure showing the gene expression of psoriasis disease markers S100A7, PI3, and DEFB4, and the pro-inflammatory cytokine CXCL10, after treating a psoriasis-like 3D skin tissue model prepared through treatment with a cytokine complex according to one embodiment of the present invention with dexamethasone, a candidate substance for psoriasis treatment. FIG. 3b is a figure showing the expression of skin barrier and epidermal cell differentiation factors filaggrin, involucrin, loricrin, and cytokeratin-10, and psoriasis disease marker S100A7 in tissue after treating a psoriasis-like 3D skin tissue model prepared by cytokine complex treatment according to one embodiment of the present invention with dexamethasone, a candidate substance for psoriasis treatment. FIG. 3c is a figure showing the identification of cells expressing Ki-67, a psoriasis disease marker, within a tissue after treating a psoriasis-like 3D skin tissue model prepared through cytokine complex treatment according to one embodiment of the present invention with dexamethasone, a candidate substance for psoriasis treatment. FIG. 4a is a figure confirming the gene expression of psoriasis disease markers S100A7 and PI3, and the pro-inflammatory cytokine CXCL10, in a psoriasis-like 3D skin tissue model prepared by treatment with a cytokine complex according to one embodiment of the present invention, and in a psoriasis-like 3D skin tissue model prepared by treatment with a cytokine complex and additionally co-culture with feeder cells. FIG. 4b is a figure showing the histopathological characteristics of a psoriasis-like 3D skin tissue model prepared by treatment with a cytokine complex according to one embodiment of the present invention, and a psoriasis-like 3D skin tissue model prepared by treatment with a cytokine complex and additionally co-culture with culture assistant cells. Specific details for implementing the invention

[0028] The present invention will be described in more detail below.

[0030] The present invention provides a method for manufacturing a psoriasis-like three-dimensional skin tissue model comprising the following steps:

[0031] (a) treating a three-dimensional skin tissue model with a cytokine complex composed of IL-7, IL-22, and TNF-α; and

[0032] (b) A step of confirming the expression of one or more of skin barrier and epidermal cell differentiation factors, psoriasis disease markers, and proinflammatory cytokines in the above-processed three-dimensional skin tissue model.

[0033] In the method of the present invention, the cells constituting the three-dimensional skin tissue model may be human keratinocytes.

[0034] In the method of the present invention, the cytokine complex may be prepared by mixing IL-7, IL-22, and TNF-α in a weight ratio of 1 to 10:1 to 10:1, specifically by mixing in a weight ratio of 1 to 8:1 to 8:1, and more specifically by mixing in a weight ratio of 1 to 6:1 to 6:1, but is not limited thereto.

[0035] In the method of the present invention, the cytokine complex may be treated at 5 to 200 ng / mL, specifically at 10 to 180 ng / mL, more specifically at 20 to 160 ng / mL, and more specifically at 25 to 150 ng / mL, but is not limited thereto.

[0036] In addition, the above cytokine complex may be treated for 12 to 108 hours, specifically for 18 to 102 hours, and more specifically for 24 to 96 hours, but is not limited thereto.

[0037] In the method of the present invention, the skin barrier and epidermal cell differentiation factors may be one or more of filaggrin, involucrin, loricrin, and cytokeratin-10, and a psoriasis-like three-dimensional skin tissue model may be obtained by confirming the expression of the skin barrier and epidermal cell differentiation factors. Specifically, a three-dimensional skin tissue model in which the expression of the skin barrier and epidermal cell differentiation factors is reduced compared to a control group may be obtained as a psoriasis-like three-dimensional skin tissue model.

[0038] In the method of the present invention, the psoriasis disease marker may be one or more of S100A7 (S100 calcium binding protein A7), PI3 (peptidase inhibitor 3), DEFB4 (defensin beta 4B), and Ki-67, and a psoriasis-like three-dimensional skin tissue model may be obtained by confirming the expression of the psoriasis disease marker. Specifically, a three-dimensional skin tissue model in which the expression of the psoriasis disease marker increases compared to the control group may be obtained as a psoriasis-like three-dimensional skin tissue model.

[0039] In the method of the present invention, the pro-inflammatory cytokine may be one or more of CXCL10 and IL-8, and a psoriasis-like three-dimensional skin tissue model may be obtained by confirming the expression of the pro-inflammatory cytokine. Specifically, a three-dimensional skin tissue model in which the expression of the pro-inflammatory cytokine increases compared to the control group may be obtained as a psoriasis-like three-dimensional skin tissue model.

[0040] Here, the control group refers to a three-dimensional skin tissue model treated with PBS (Phosphate-Buffered Saline) or DMSO (Dimethyl sulfoxide).

[0041] In the method of the present invention, the expression confirmation may be the expression of a protein or a gene, and such expression may be confirmed by one or more of quantitative RT-PCR (Reverse transcription polymerase chain reaction), real-time RT-PCR, immunofluorescence, immunoblot analysis, enzyme immunoassay (ELISA), and immunohistochemical staining, but is not limited thereto.

[0042] In the method of the present invention, the three-dimensional skin tissue model of step (a) may further include co-culturing with feeder cells. Specifically, in step (a), the three-dimensional skin tissue model may be treated with a cytokine complex composed of IL-7, IL-22, and TNF-α and co-cultured with feeder cells, thereby obtaining a psoriasis-like three-dimensional skin tissue model that more accurately embodies the characteristics of psoriasis. For example, psoriasis is a pathological characteristic characterized by thickening of the stratum corneum, which is induced by an abnormally increased proliferative capacity of keratinocytes in the basal layer. The three-dimensional skin tissue model treated with the cytokine complex and co-cultured with feeder cells has improved intercellular signaling and enhanced proliferative capacity and stem cell activity of keratinocytes, thereby more accurately embodying the characteristics of psoriasis.

[0043] In addition, the culture helper cells may be fibroblasts, for example, mouse or human fibroblasts, but are not limited thereto.

[0044] In addition, the culture-assisting cells are 0.1 to 50 × 10 5 It can be co-cultured with a cell count of 0.5 to 30 × 10 5 It can be co-cultured with a cell count of 1 to 10 × 10 5 It can be co-cultured with a cell count of 1 to 5 × 10⁶ 5It may be co-cultured with a cell count, but is not limited thereto.

[0045] In the method of the present invention, parakeratosis, psoriatic hyperplasia, or interepithelial electrical resistance (TEER) can be further identified in the three-dimensional skin tissue model of step (b). Specifically, a three-dimensional skin tissue model exhibiting parakeratosis or psoriatic hyperplasia can be obtained as a psoriasis-like three-dimensional skin tissue model, and a three-dimensional skin tissue model in which interepithelial electrical resistance (TEER) increases compared to a control group can be obtained as a psoriasis-like three-dimensional skin tissue model. Here, the control group refers to a three-dimensional skin tissue model treated with PBS or DMSO.

[0047] In addition, the present invention provides a psoriasis-like three-dimensional skin tissue model manufactured by the method according to the present invention.

[0048] In the present invention, the expression of one or more skin barrier and epidermal cell differentiation factors, specifically filaggrin, involucrin, loricrin, and cytokeratin-10, is reduced compared to the control group in the psoriasis-like three-dimensional skin tissue model.

[0049] In the present invention, the psoriasis-like three-dimensional skin tissue model has increased expression of psoriasis disease markers, specifically one or more of S100A7, PI3, DEFB4, and Ki-67, compared to the control group.

[0050] In the present invention, the psoriasis-like three-dimensional skin tissue model has increased expression of pro-inflammatory cytokines, specifically one or more of CXCL10 and IL-8, compared to the control group.

[0051] In the present invention, the psoriasis-like three-dimensional skin tissue model exhibits hyperkeratosis and psoriatic hyperplasia, and the interepithelial electrical resistance (TEER) is increased compared to the control group.

[0052] Here, the control group refers to a three-dimensional skin tissue model treated with PBS or DMSO.

[0054] In addition, the present invention provides a screening method for psoriasis therapeutic agents using a psoriasis-like three-dimensional skin tissue model comprising the following steps:

[0055] (a) a step of treating a psoriasis-like three-dimensional skin tissue model prepared by the method according to the present invention with a psoriasis therapeutic agent candidate; and

[0056] (b) A step of confirming the expression of one or more of skin barrier and epidermal cell differentiation factors, psoriasis disease markers and pro-inflammatory cytokines in a skin tissue model treated with the above psoriasis treatment candidate substance.

[0057] In the method of the present invention, the skin barrier and epidermal cell differentiation factor may be one or more of filaggrin, involucrin, loricrin, and cytokeratin-10, and a candidate substance may be selected as a psoriasis treatment by confirming the expression of the skin barrier and epidermal cell differentiation factor. Specifically, a candidate substance that increases the expression of the skin barrier and epidermal cell differentiation factor compared to a control group may be selected as a psoriasis treatment.

[0058] In the method of the present invention, the psoriasis disease marker may be one or more of S100A7, PI3, DEFB4, and Ki-67, and a candidate substance may be selected as a psoriasis treatment by confirming the expression of the psoriasis disease marker. Specifically, a candidate substance that reduces the expression of the psoriasis disease marker compared to a control group may be selected as a psoriasis treatment.

[0059] In the method of the present invention, the pro-inflammatory cytokine may be one or more of CXCL10 and IL-8, and a candidate substance may be selected as a psoriasis treatment by confirming the expression of the pro-inflammatory cytokine. Specifically, a candidate substance that reduces the expression of the pro-inflammatory cytokine compared to a control group may be selected as a psoriasis treatment.

[0060] Here, the control group refers to a psoriasis-like 3D skin tissue model untreated with a psoriasis treatment candidate, or a psoriasis-like 3D skin tissue model treated with PBS or DMSO.

[0061] In the method of the present invention, the expression confirmation may be the expression of a protein or a gene, and such expression may be confirmed by one or more of quantitative RT-PCR, real-time RT-PCR, immunofluorescence, immunoblot analysis, enzyme immunoassay (ELISA), and immunohistochemical staining, but is not limited thereto.

[0062] In the method of the present invention, the candidate substance may be selected as a psoriasis treatment by further confirming hyperkeratosis, psoriatic hyperplasia, or interepithelial electrical resistance (TEER) in a skin tissue model treated with the psoriasis treatment candidate substance of step (b). Specifically, a candidate substance that reduces hyperkeratosis or psoriatic hyperplasia or reduces interepithelial electrical resistance (TEER) compared to a control group may be selected as a psoriasis treatment.

[0064] The present invention will be explained in detail below through examples.

[0065] However, the following examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following examples.

[0067] <Example 1> Preparation of a psoriasis-like 3D skin tissue model

[0068] <1-1> 3D Skin Model

[0069] 3D Skin Model (KeraSkin TMThe 3D skin model (Biosolution) consists of 8 to 15 cell layers composed of normal human epithelial keratinocytes (NHEK) derived from penile foreskin tissue or adult breast tissue, which is similar to in vivo epithelial tissue having basal, spinous, granular, and cornified layers. In addition, the 3D skin model has metabolic and cell division activities and expresses mature epithelial-specific differentiation markers such as pro-filaggrin, K1 / K10 cytokeratin pair, involucrin, and type I epidermal transglutaminase. The above three-dimensional skin model can be cultured in DMEM (Dulbecco's Modified Eagle's Medium) containing epidermal growth factor, insulin, hydrocortisone, antibiotics, etc., while maintaining normal epidermal morphology for up to 5 weeks.

[0071] <1-2> Cytokine mix treatment

[0072] A 3D skin model of Example <1-1> was cultured using the Biosolution culture method, and then a cytokine complex of IL-7, IL-22, and TNF-α mixed in a ratio of 5:5:1 was added to the culture medium at 60 ng / mL for 78 hours to produce a psoriasis-like 3D skin tissue model.

[0074] <1-3 > Treatment with Cytokine Mix and Co-culture with Feeder Cells

[0075] The 3D skin model of Example <1-1> above was cultured using the Biosolution culture method, and then 66 ng / mL of a cytokine complex prepared by mixing IL-7, IL-22, and TNF-α in a ratio of 5:5:1 was applied to the culture medium for 78 hours, and 2.5 × 10 5 A psoriasis-like 3D skin tissue model was prepared by co-culturing feeder cells of cell-to-well ratio in the culture medium. 3T3 cells or human fibroblasts were used as feeder cells.

[0077] <Experimental Example 1> Confirmation of Psoriasis-Related Factor Expression in a Psoriasis-Like 3D Skin Tissue Model Prepared via Cytokine Complex Treatment

[0078] In the psoriasis-like 3D skin tissue model prepared in Example <1-2> above, the gene expression of skin barrier and epidermal cell differentiation factors such as filaggrin (FLG), involucrin (IVL), loricrin (LOR), and keratin-10 (also known as keratin-10, KRT10, or cytokeratin-10 (CK10)), psoriasis disease markers such as S100A7 (S100 calcium binding protein A7), PI3 (peptidase inhibitor 3), and DEFB4 (defensin beta 4B), and proinflammatory cytokines such as CXCL10 (CXC motif chemokine ligand 10) and IL-8 (interleukin 8) was confirmed by real-time quantitative PCR.

[0079] Specifically, a 3D skin model was treated with a cytokine complex in the same manner as in Example <1-2> above, and then the 3D skin model was harvested. Next, the TRIzol reagent was added, and RNA was extracted according to the manufacturer's method. cDNA was synthesized from the extracted RNA using a cDNA synthesis kit (TaKaRa, Japan) according to the manufacturer's method. Real-time polymerase chain reaction was performed using the prepared cDNA as a template and the primers listed in [Table 1] below. In addition, a 3D skin model treated with PBS (Phosphate-Buffered Saline) instead of the cytokine complex was used as a control (Figs. 1a to 1c).

[0080] primer Sequence (5'→3') Sequence number FLG Forward direction AGACACTCTCAGCACGGAAG 1 reverse direction GGCCACATAAACCTGGGTCC 2 IVL Forward direction GCTCCTCAAGACTGTTCCTCC 3 reverse direction CAGGCAGTCCCTTTACAGCA 4 LOR Forward direction TCTCATGATGCTACCCGAGGTTTG 5 reverse direction GGGTTGGGAGGTAGTTGTACAGAA 6 KRT10 Forward direction CAACTCACATCAGGGGGAGC 7 reverse direction AGCCTGGCATTGTCGATCTG 8 S100A7 Forward direction ACTCAAGCTGAGAGGTCCATA 9 reverse direction ACATCGGCGAGGTAATTTGT 10 PI3 Forward direction CAAAGGCCGTGTTCCATTCA 11 reverse direction GGCGCACCGGATCAAGATAA 12 DEFB4 Forward direction GATGCCTCTTCCAGGTGTTTTT 13 reverse direction GGATGACATATGGCTCCACTCTT 14 CXCL10 Forward direction CCTGCAAGCCAATTTTGTCCA 15 reverse direction AGACCTTTCCTTGCTAACTGCT 16 IL-8 Forward direction TTCTGCAGCTCTGTGTGAAGG 17 reverse direction TAATTTCTGTGTTGGCGCAGTG 18 GAPDH Forward direction CAAATTCCATGGCACCGTCA 19 reverse direction GACTCCACGACGTACTCAGC 20

[0081] As a result, as shown in Fig. 1a, the control group (KeraSkin TM Compared to the psoriasis-like 3D skin tissue model (KeraSkin-PS) prepared in Example <1-2> above TM In ), the expression of the genes IVL, FLG, LOR, and KRT10, which are skin barrier and epidermal cell differentiation factors, was significantly reduced.

[0082] In addition, as shown in Fig. 1b, the control group (KeraSkin TM Compared to the psoriasis-like 3D skin tissue model (KeraSkin-PS) prepared in Example <1-2> above TM Gene expression of psoriasis disease markers DEFB4, PI3, and S100A7 was significantly increased in ).

[0083] In addition, as shown in Fig. 1c, the control group (KeraSkin TM Compared to the psoriasis-like 3D skin tissue model (KeraSkin-PS) prepared in Example <1-2> above TM The gene expression of the pro-inflammatory cytokines CXCL10 and IL-8 was significantly increased in ).

[0084] From the above results, it can be seen that the three-dimensional skin tissue model prepared through cytokine complex treatment according to the method of the present invention exhibits psoriasis-like findings.

[0086] <Experimental Example 2> Confirmation of Histopathological and Physical Changes in a Psoriasis-like 3D Skin Tissue Model Prepared via Cytokine Complex Treatment

[0087] Histopathological changes in the psoriasis-like 3D skin tissue model prepared in Example <1-2> were confirmed by H&E staining, and physical changes were confirmed by measuring interepithelial electrical resistance (TEER).

[0088] Specifically, a cytokine complex was treated on a 3D skin model in the same manner as in Example <1-2> above, and then the 3D skin model was harvested, fixed in 4% formaldehyde (Sigma, USA), and embedded in paraffin to prepare slides. The tissue slides were stained with hematoxylin and eosin (H&E), and histopathological changes were observed using an optical microscope (Olympus, Tokyo, Japan) (Fig. 2a).

[0089] In addition, a 3D skin model was treated with a cytokine complex in the same manner as in Example <1-2>, the 3D skin model was collected and placed in a bath, and the epithelial potential difference and short-circuit current were determined using an Ag-AgCl electrode with a voltage clamp corrected for fluid resistance, and the interepithelial electrical resistance (TEER) was calculated according to Ohm's law. Additionally, a 3D skin model treated with PBS instead of the cytokine complex was used as a control (Fig. 2b).

[0090] As a result, as shown in Fig. 2a, in the psoriasis-like 3D skin tissue model prepared in Example <1-2>, parakeratosis (cell nuclei remaining in the keratin, red arrow) and psoriatic hyperplasia (the keratin layer thickens and the granular layer decreases) were observed, and it was found that the keratin layer thickened.

[0091] In addition, as shown in Fig. 2b, the control group (KeraSkin TM Compared to the psoriasis-like 3D skin tissue model (KeraSkin-PS) prepared in Example <1-2> above TM It showed physical characteristics of increasing TEER in ).

[0092] From the above results, it can be seen that the three-dimensional skin tissue model prepared through cytokine complex treatment according to the method of the present invention exhibits psoriasis-like findings.

[0094] <Experimental Example 3> Screening of Psoriasis Treatment Agents Using a Psoriasis-like 3D Skin Tissue Model Prepared by Cytokine Complex Treatment

[0095] After treating the psoriasis-like 3D skin tissue model prepared in Example <1-2> with dexamethasone as a candidate drug for psoriasis treatment, the gene expression of PI3, S100A7, DEFB4, and CXCL10 was confirmed by real-time polymerase chain reaction. In addition, the expression of filaggrin, involucrin, loricrin, cytokeratin-10, S100A7, and Ki67 in the tissue was confirmed by immunohistochemical staining.

[0096] Specifically, a cytokine complex was treated to a 3D skin model using the method described in Example <1-2> above, followed by treatment with dexamethasone (DEX) either untreated or at 100 μM for 24 hours. After 24 hours, the 3D skin model was collected, and real-time polymerase chain reaction was performed using the same method described in Experimental Example 1 above to confirm the gene expression of PI3, S100A7, DEFB4, and CXCL10 (Fig. 3a).

[0097] In addition, 3D skin models were collected using the same method as above, either untreated or treated with 20 μM dexamethasone (DEX) for 48 hours. The collected 3D skin models were then fixed in 4% formaldehyde (Sigma, USA) and embedded in paraffin to prepare slides. The tissue slides were deparinized using xylene and dehydrated using alcohol. Afterward, the slides were immersed in citrate buffer, microwaved for 10 minutes, and cooled at room temperature for one hour. The slides were washed with distilled water, reacted with 5% goat serum at room temperature for one hour, and then incubated with antibodies for each factor diluted 1:50. After reacting with HRP-conjugated secondary antibodies, color development was performed using a DAB kit to confirm changes in the expression of filaggrin, involucrin, loricrin, cytokeratin-10, S100A7, and Ki-67 within the tissue. In the above experiment, a 3D skin model treated with PBS instead of the cytokine complex was used as a control (Figs. 3b and 3c).

[0098] As a result, as shown in FIG. 3a, the psoriasis-like 3D skin tissue model (KeraSkin-PS) prepared in Example <1-2> above TM Compared to ), in the case treated with dexamethasone (KeraSkin-PS TM + Dexamethasone) Gene expression of PI3, S100A7, DEFB4 and CXCL10 was reduced.

[0099] In addition, as shown in Fig. 3b, the control group (KeraSkin TM Compared to the psoriasis-like 3D skin tissue model (KeraSkin-PS) prepared in Example <1-2> above TM The expression of filaggrin, involucrin, loricrin, and CK10 in the tissue decreased, while the expression of S100A7 increased, whereas in the case of dexamethasone treatment (KeraSkin-PS TM+ Dexamethasone) These expressions were restored to a level similar to the control group.

[0100] In addition, as shown in Fig. 3c, the control group (KeraSkin TM Compared to the psoriasis-like 3D skin tissue model (KeraSkin-PS) prepared in Example <1-2> above TM While the number of cells expressing Ki-67, a marker directly associated with parakeratosis and psoriatic hyperplasia, increases within the tissue, in the case of dexamethasone treatment (KeraSkin-PS TM The number of cells expressing Ki-67 (+ Dexamethasone) decreased.

[0101] From the above results, it can be seen that the three-dimensional skin tissue model prepared through cytokine complex treatment according to the method of the present invention can be used as a psoriasis-like three-dimensional skin tissue model for screening psoriasis treatments.

[0103] <Experimental Example 4> Confirmation of psoriasis-related factor expression in a psoriasis-like 3D skin tissue model prepared through cytokine complex treatment and co-culture of culture assistant cells

[0104] Gene expression of PI3, S100A7, and CXCL10 in the psoriasis-like 3D skin tissue model prepared in the above Examples <1-3> was confirmed by real-time polymerase chain reaction, and histopathological changes were confirmed by H&E staining.

[0105] Specifically, a cytokine complex was treated to a 3D skin model in the same manner as in Example <1-3>, and after co-culturing with culture assistant cells, the 3D skin model was harvested. Then, real-time polymerase chain reaction (Fig. 4a) and H&E staining (Fig. 4b) were performed in the same manner as described in Experimental Example 1 and Experimental Example 2. In addition, gene expression was compared with the 3D skin model of Example <1-1> and the psoriasis-like 3D skin tissue model prepared through the cytokine complex treatment of Example <1-2>.

[0106] As a result, as shown in Fig. 4a, the control group (KeraSkinTM Compared to the psoriasis-like 3D skin tissue model (KeraSkin-PS) prepared in Examples <1-3> above TM The gene expression of PI3, S100A7, and CXCL10 was significantly increased in the (with feeder cell). In addition, the psoriasis-like 3D skin tissue model (KeraSkin-PS) prepared in Example <1-2> above was used. TM It was found that the expression of these genes increased significantly even compared to (no feeder cell).

[0107] In addition, as shown in FIG. 4b, the psoriasis-like 3D skin tissue model (KeraSkin-PS) prepared in Example <1-2> above TM Compared to the psoriasis-like 3D skin tissue model (KeraSkin-PS) prepared in Examples <1-3> above (no feeder cell), TM It was found that cell density increased in the basal layer (with feeder cells), confirming that the proliferative capacity of keratinocytes in the basal layer increased.

[0108] Through the above results, it can be seen that the 3D skin tissue model prepared by cytokine complex treatment and co-culture of culture-assisted cells according to the method of the present invention is a psoriasis-like 3D skin tissue model in which the characteristics of dryness are more accurately realized.

Claims

Claim 1 A method for preparing a psoriasis-like 3D skin tissue model comprising the following steps: (a) treating a 3D skin tissue model with a cytokine complex composed of IL-7, IL-22, and TNF-α for 24 to 96 hours; (b) further treating the 3D skin tissue model treated with the cytokine complex in step (a) with feeder cells and co-culturing the 3D skin tissue model; and (c) obtaining a 3D skin tissue model as a psoriasis-like 3D skin tissue model from the co-cultured 3D skin tissue model of step (b), having one or more of the following features compared to a control group untreated with the cytokine complex and feeder cells: (i) decreased expression of skin barrier and epidermal cell differentiation factors; (ii) increased expression of psoriasis disease markers; and (iii) increased expression of proinflammatory cytokines. Claim 2 A method for manufacturing a psoriasis-like three-dimensional skin tissue model, wherein, in step (a), the cells constituting the three-dimensional skin tissue model are human keratinocytes. Claim 3 A method for preparing a psoriasis-like three-dimensional skin tissue model according to claim 1, wherein in step (a), the cytokine complex is treated at 5 to 200 ng / mL for 24 to 96 hours. Claim 4 A method for preparing a psoriasis-like three-dimensional skin tissue model according to claim 1, wherein the skin barrier and epidermal cell differentiation factors are one or more of filaggrin, involucrin, loricrin, and cytokeratin-10. Claim 5 delete Claim 6 A method for preparing a psoriasis-like three-dimensional skin tissue model according to claim 1, wherein the psoriasis disease marker is one or more of S100A7 (S100 calcium binding protein A7), PI3 (peptidase inhibitor 3), DEFB4 (defensin beta 4B), and Ki-67. Claim 7 delete Claim 8 A method for preparing a psoriasis-like three-dimensional skin tissue model according to claim 1, wherein the pro-inflammatory cytokine is one or more of CXCL10 and IL-8. Claim 9 delete Claim 10 delete Claim 11 A method for preparing a psoriasis-like three-dimensional skin tissue model, wherein, in step (b) above, the culture-assisting cells are fibroblasts. Claim 12 A method for preparing a psoriasis-like three-dimensional skin tissue model according to claim 1, wherein in step (c), the confirmation of expression is confirmed by one or more of quantitative RT-PCR (Reverse transcription polymerase chain reaction), real-time RT-PCR, immunofluorescence, immunoblot analysis, enzyme immunoassay (ELISA), and immunohistochemical staining. Claim 13 A method for manufacturing a psoriasis-like 3D skin tissue model according to claim 1, wherein parakeratosis, psoriatic hyperplasia, or interepithelial electrical resistance (TEER) is additionally identified in the 3D skin tissue model of step (c). Claim 14 A method for manufacturing a psoriasis-like 3D skin tissue model according to claim 13, wherein the 3D skin tissue model exhibiting parakeratosis or psoriasis-like hyperplasia is obtained as a psoriasis-like 3D skin tissue model. Claim 15 A method for manufacturing a psoriasis-like 3D skin tissue model according to claim 13, wherein the 3D skin tissue model having increased interepithelial electrical resistance (TEER) compared to the control group is obtained as a psoriasis-like 3D skin tissue model. Claim 16 delete Claim 17 A screening method for a psoriasis therapeutic agent using a psoriasis-like three-dimensional skin tissue model comprising the following steps: (a) treating a psoriasis-like three-dimensional skin tissue model prepared by the method of any one of claims 1 to 4, 6, 8, and 11 to 15 with a psoriasis therapeutic agent candidate; and (b) confirming the expression of one or more of a skin barrier and epidermal cell differentiation factor, a psoriasis disease marker, and a pro-inflammatory cytokine in the skin tissue model treated with the psoriasis therapeutic agent candidate.

Citation Information

Patent Citations

  • A method for preparing a three-dimentional psoriasis skin model using IL-17A

    KR1020220094894A